|
Market Cap (2-Jul) $1,802,916,992 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (19-Jun) 7,497,069 (6.03%) (29th) |
|
52w High $22.44 |
52w Low $8.61 |
P/E 83.33 |
EPS 1.09 |
NEU released this announcement to the ASX on 30 June 2023, 9:36. The announcement is marked as price sensitive, and is 2 page(s) in length and 128.16kb in size.
This is the most recent announcement released by NEU to the ASX. You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.719% short sold according to ASIC data. It was ranked the 264th most shorted stock on the ASX. It is now ranked as the 29th most shorted stock on the ASX with 6.027% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| Neuren receives US$40m milestone payment | 7 June 2023, 15:19 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 